Current Clinical Trials
The following clinical research initiatives are being conducted in our division:
⨀ Hypereosinophilic Syndrome:
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (NATRON) (PI: Bressler)
This is a randomized, double-blind, 24-week Phase III study to compare the efficacy and safety of benralizumab vs. placebo administered by SC injections every 4 weeks in patients with hypereosinophilic syndorome (HES). Patients will be randomized to receive either benralizumab or placebo during the 24-week study period. The target population is adult patients with symptomatic active HES.
| Principal Investigator: | Peter Bressler, MD |
| Status: | On-Hold |
| IRB Number: | Pro00103948 |
| Clinical Trials.gov #: | NCT04191304 |
| Study Team Contact: | Jessica Shier – jessica.shier@duke.edu |
Enroll in a Pulmonary Clinical Trial at Duke
Researchers in our division are investigating a variety of treatments and therapies to respond to lung disease.
Click here to view a list of current clinical trials for Pulmonary.